Phathom (PHAT) accounting chief surrenders RSU shares for taxes

Rhea-AI Filing Summary

Phathom Pharmaceuticals, Inc. insider updates share holdings. Principal Accounting Officer Robert Charles Breedlove reported the surrender of 776 shares of common stock on 01/21/2026 at a price of $13.61 per share. According to the footnote, these shares represent stock underlying restricted stock units that were surrendered to Phathom to cover tax withholding obligations, rather than an open-market sale. After this transaction, Breedlove beneficially owned 47,068 shares of Phathom common stock directly and 6,945.4 shares indirectly through a 401(k) plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Breedlove Robert Charles

(Last) (First) (Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK NJ 07932

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		F(1)		776	D	$13.61	47,068	D
Common Stock								6,945.4	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.

	/s/ Robert Charles Breedlove	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PHAT’s Principal Accounting Officer report?

Principal Accounting Officer Robert Charles Breedlove reported a transaction in Phathom Pharmaceuticals, Inc. (PHAT) common stock on 01/21/2026. He surrendered 776 shares at $13.61 per share, tied to restricted stock units.

Was the PHAT insider transaction an open-market sale?

No. A footnote explains the 776 shares represented stock underlying restricted stock units that were surrendered to Phathom Pharmaceuticals, Inc. to satisfy the company’s tax withholding obligation, not a discretionary open-market sale.

How many PHAT shares does Robert Charles Breedlove own after this Form 4?

After the reported transaction, Robert Charles Breedlove beneficially owned 47,068 shares of Phathom common stock directly and 6,945.4 shares indirectly through a 401(k) plan.

What does transaction code "F" mean in the PHAT Form 4 filing?

Transaction code "F" indicates a transaction related to the payment of tax obligations, in this case shares underlying restricted stock units surrendered to Phathom Pharmaceuticals, Inc. for tax withholding.

What is the role of the reporting person in Phathom Pharmaceuticals (PHAT)?

The reporting person, Robert Charles Breedlove, serves as an officer of Phathom Pharmaceuticals, Inc. with the title Principal Accounting Officer, as indicated in the filing.

How are some of the PHAT shares held by the insider classified?

In addition to directly held shares, the filing shows 6,945.4 shares of Phathom common stock held indirectly by the reporting person through a 401(k) plan.